The Manila Times

Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Mi…

Phase 1 study of REX-8756 is well underway following FDA clearance of the Investigational New Drug (IND) application in ...

Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen

A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual agonist, PG-102, ...
The Manila Times

VarmX and Rentschler Biopharma partner to advance novel coagulation therapy toward Phase 3 and commercialization

VarmX and Rentschler Biopharma partner to advance novel coagulation therapy toward Phase 3 and commercialization ...
Nasdaq

Gyre Therapeutics Reports Q1 2025 Revenue of $22.1 Million and Progress in Clinical Development and Commercialization Efforts

Gyre Therapeutics reported Q1 2025 revenue of $22.1 million and provided updates on clinical trials and product launches. Gyre Therapeutics reported Q1 2025 revenue of $22.1 million and a GAAP basic ...